Bibliography
- Stebbing J , BowerM: What can oncologists learn from HIV?Lancet Oncol.4, 438–445 (2003).
- Stebbing J , BowerM: Comparative pharmacogenomics of antiretroviral and cytotoxic treatments.Lancet Oncol.7, 61–68 (2006).
- Bowen RL , StebbingJ, JonesLJ: A review of the ethnic differences in breast cancer:Pharmacogenomics7, 935–942 (2006).
- Hamelin BA , BouayadA, MethotJ et al.: Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin. Pharmacol. Ther.67, 466–477 (2000).
- Forbes JF : The control of breast cancer: the role of tamoxifen.Semin. Oncol.24, S1–5–S1–19 (1997).
- Michalides R , GriekspoorA, BalkenendeA et al.: Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell5, 597–605 (2004).
- Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365, 1687–1717 (2005).
- DeVita VT Jr: The concept of cure. Nat. Clin. Pract. Oncol.3, 59 (2006).
- Lien EA , SolheimE, LeaOA, LundgrenS, KvinnslandS, UelandPM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.Cancer Res.49, 2175–2183 (1989).
- Sridar C , KentUM, NotleyLM, GillamEM, HollenbergPF: Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6.J. Pharmaco.l Exp. Ther.301, 945–952 (2002).
- Coller JK , KrebsfaengerN, KleinK et al.: The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br. J. Clin. Pharmacol.54, 157–167 (2002).
- Johnson MD , ZuoH, LeeKH et al.: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat.85, 151–159 (2004).
- Stearns V , JohnsonMD, RaeJM et al.: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst.95, 1758–1764 (2003).
- Bradford LD : CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.Pharmacogenomics3, 229–243 (2002).
- Jin Y , DestaZ, StearnsV et al.: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst.97, 30–39 (2005).
- Goetz MP , RaeJM, SumanVJ et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol.23, 9312–9318 (2005).
- Ingle JN , SumanVJ, MailliardJA et al.: Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89–30–52. Breast Cancer Res. Treat.98, 217–222 (2006).
- Bonanni B , MacisD, MaisonneuveP et al.: Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J. Clin. Oncol.24, 3708–3709 (2006).
- Wegman P , VainikkaL, StalO et al.: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res.7, R284–R290 (2005).
- Rae JM , GoetzMP, HayesDF et al.: CYP2D6 genotype and tamoxifen response. Breast Cancer Res.7, E6 (2005).
- Nowell SA , AhnJ, RaeJM et al.: Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat.91, 249–258 (2005).
- Borges S , DestaZ, LiL et al.: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther.80, 61–74 (2006).
- Loprinzi CL , KuglerJW, SloanJA et al.: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet356, 2059–2063 (2000).
- Loprinzi CL , SloanJA, PerezEA et al.: Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol.20, 1578–1583 (2002).
- Stearns V , BeebeKL, IyengarM, DubeE: Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.JAMA.289, 2827–2834 (2003).
- Goetz MP , KnoxSK, SumanVJ et al.: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat.(2006) (Epub ahead of print).
- Coombes RC , HallE, GibsonLJ et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med.350, 1081–1092 (2004).